Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 05, 2024

BUY
$0.22 - $0.66 $2,200 - $6,600
10,000 Added 100.0%
20,000 $7,000
Q1 2022

Apr 28, 2022

BUY
$1.22 - $2.03 $12,200 - $20,299
10,000 New
10,000 $18,000

Others Institutions Holding OTLK

About Outlook Therapeutics, Inc.


  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.18B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Crew Capital Management, Ltd. Portfolio

Follow Crew Capital Management, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crew Capital Management, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Crew Capital Management, Ltd. with notifications on news.